| Pharmaceutical Information |
| Drug Name |
Bacillus calmette-guerin |
| Drug ID |
BADD_D00207 |
| Description |
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others. |
| Indications and Usage |
Not Available |
| Marketing Status |
approved; investigational |
| ATC Code |
L03AX03 |
| DrugBank ID |
DB12768
|
| KEGG ID |
Not Available
|
| MeSH ID |
D001500
|
| PubChem ID |
6451
|
| TTD Drug ID |
D0A8LZ
|
| NDC Product Code |
0052-0602 |
| UNII |
8YGN0Y942M
|
| Synonyms |
BCG Vaccine | Vaccine, BCG | Bacillus Calmette Guerin Vaccine | Calmette's Vaccine | Calmette Vaccine | Calmettes Vaccine | Vaccine, Calmette's | Calmette Guerin Bacillus Vaccine |
|
| Chemical Information |
| Molecular Formula |
C21H14Br4O5S |
| CAS Registry Number |
76-60-8 |
| SMILES |
CC1=C(C(=C(C=C1C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4C)Br)O)Br)Br)O)Br |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
